SISRAM MED's unaudited revenue for the third quarter achieved double-digit year-on-year growth and will orderly advance the commercialization process of Daxifei in mainland China
SISRAM MED achieved double-digit year-on-year growth in unaudited revenue in the third quarter of 2025, mainly due to strong performance in the markets of China, South Korea, and Thailand. The group will continue to drive the penetration of the Soprano series in the Asia-Pacific region and accelerate the commercial deployment of Universkin by Alma in the U.S. market, while orderly advancing the commercialization process of Daxifei in mainland China
According to the Zhitong Finance APP, SISRAM MED (01696) announced that the group's new orders in the third quarter of 2025 maintained a strong growth momentum, mainly benefiting from the performance in the markets of China, South Korea, and Thailand. The multifunctional flagship device Alma Harmony achieved steady growth in this quarter. As a result, the group's unaudited revenue for this quarter achieved a year-on-year double-digit growth.
With continuous market expansion and demand exploration, the group will further promote the penetration of the Soprano series in the Asia-Pacific region within the year and fully advance the commercial deployment of Universkin by Alma in the U.S. market. At the same time, the commercialization process of Daxifei in mainland China will be advanced in an orderly manner as planned
